Friday, February 28, 2025 Dear Shareholders and Investors, Ninety day periods offer a short-term snapshot of a company, but it is more instructive to look at the bigger, longer-term picture. The direction of NAT is unquestionably upwards as we create room for profitable growth.
Nordic American Tankers' stock has declined by 26% since my last report, trending inline with weaker tanker rates. At current tanker rates, analyst estimates are likely too optimistic for 2025. Using more realistic assumptions, I believe NAT is fairly valued at 10x Fwd P/E. On the plus side, NAT's 6% dividend appears safe given current tanker rates. This could support the stock's valuation.
REPEAT Wednesday, February 5, 2025 Dear Shareholders and Investors, A major project for 2025 is to renew and grow our fleet. We plan to buy two or three ships and to sell two or three.
Wednesday, February 5, 2025 Dear Shareholders and Investors, A major project for 2025 is to renew and grow our fleet. We plan to buy two or three ships and to sell two or three.
While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Wednesday, January 22, 2025 Dear Shareholders and Investors, In the recent past, NAT has carried through several transactions, reflecting a very active period. NAT has declared the purchase option for a 2018-built Suezmax tanker on favorable terms from a close financing partner.
Monday, January 6, 2025 Dear Shareholders and Investors, Non-Executive Vice Chairman of NAT, Alexander Hansson, has today bought 300,000 shares at $2.54 per share. He is now holding 4,000,000 shares.
Tuesday, December 17, 2024 Dear Shareholders and Investors, Non-Executive Vice Chairman of NAT, Alexander Hansson, has today bought 100,000 shares at $2.5125 per share. He is now holding 3,700,000 shares.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.